Genentech/Novartis Xolair Approval Could Be Delayed Until Early 2002
Executive Summary
Genentech/Novartis Xolair (omalizumab) approval could be pushed back to early 2002 as the companies prepare to submit additional safety data to FDA.
You may also be interested in...
Genentech/Novartis Xolair Indication Narrowed To Adult Allergic Asthma
Genentech and Novartis will seek a narrower label for the asthma biologic Xolair following the receipt of a "complete response" letter from FDA July 5.
Genentech/Novartis Xolair Indication Narrowed To Adult Allergic Asthma
Genentech and Novartis will seek a narrower label for the asthma biologic Xolair following the receipt of a "complete response" letter from FDA July 5.
Genentech Xolair Brand Awareness Reaches 55% Among Allergists
Brand awareness of Genentech's asthma drug Xolair (omalizumab) is over 50% among allergists as a result of Genentech's market preparation efforts, compared to 48% in the first quarter, Chief Operating Officer Myrtle Potter reported during an analyst meeting in New York City Feb. 21.